<?xml version="1.0" encoding="UTF-8"?>
<p>Indolylazole derivatives are a new class of azole antifungal drugs
 <xref rid="CIT0012" ref-type="bibr">
  <sup>12</sup>
 </xref> which have demonstrated 
 <italic>inÂ vitro</italic> activities against 
 <italic>Aspergillus</italic>
 <xref rid="CIT0013" ref-type="bibr">
  <sup>13</sup>
 </xref> and protozoa such as 
 <italic>Leishmania</italic>
 <xref rid="CIT0014" ref-type="bibr">
  <sup>14</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0015" ref-type="bibr">
  <sup>15</sup>
 </xref>. More recently, structural modifications were done to enable a specific and broad activity against 
 <italic>Candida</italic> spp., including fluconazole low-susceptible species as 
 <italic>C. krusei</italic> and 
 <italic>C. glabrata</italic>.
</p>
